Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Basic Trial Information
Trial Description
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedTissue collection/RepositoryActive0 months to 30 yearNCI, OtherABTR01B1
NCI-2009-00324, CDR0000271415, COG-ABTR01B1, U10CA098543, NCT00898079

Trial Description


This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.

Further Study Information


I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.

II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.

III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.


Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.

Eligibility Criteria

Inclusion Criteria:

  • Meets any of the following criteria:
  • Diagnosed with primary neoplasm
  • Developed a second malignant neoplasm
  • Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
  • Must have biological specimens including solid tumors and leukemias available
  • Solid tumors meeting the following criteria:
  • Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
  • Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
  • Pleural fluid or cytologic specimens meeting the following criteria:
  • At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
  • Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
  • 3-6 mL of bone marrow aspirate and 10 mL of whole blood
  • Not eligible for disease-specific biology or banking protocol

Trial Contact Information

Trial Lead Organizations/Sponsors

Children's Oncology Group

National Cancer Institute

Nilsa Ramirez, MDPrincipal Investigator

Trial Sites

New Jersey
  New Brunswick
 Saint Peter's University Hospital
 Stanley Calderwood Ph: 732-745-8600ext6163

See All Trial Sites

Link to the current record.
NLM Identifer NCT00898079 processed this data on April 09, 2015

Note: Information about this trial is from the database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the record to standardize the names of study sponsors, sites, and contacts. only lists sites that are recruiting patients for active trials, whereas lists all sites for all trials. Questions and comments regarding the presented information should be directed to

Back to TopBack to Top